Apogee Therapeutics slid roughly 15% after releasing results from a clinical trial of its eczema antibody. The drug showed a 71% reduction in severity over 16 weeks, versus 34% for the placebo. The stock is still up 23% over the past quarter.
Join our Mailing list!
Sign up to get all the latest financial news and business updates.
Please fill in the form and we will get in touch with you shortly and help answer any questions you may have about Offshore Supporting services.
